Center for Advanced Multi-Omic Characterization of Cancer

癌症高级多组学表征中心

基本信息

批准号：
10755578
负责人：
Tao Liu
金额：
$ 51.68万
依托单位：
BATTELLE PACIFIC NORTHWEST LABORATORIES
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-06-01 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10755578
关键词：
Acceleration Acute Myelocytic Leukemia Acute T Cell Leukemia Cells Center for Translational Science Activities Child Childhood Childhood Leukemia Clinical Clinical Trials Collaborations Colorectal Cancer Communities Country Data Data Analyses Defect Disease Funding Future Genome Genomics Immunotherapy Investments Label Laboratories Liquid Chromatography Malignant Childhood Neoplasm Malignant Neoplasms Malignant neoplasm of ovary Mass Spectrum Analysis Molecular National Cancer Institute Pacific Northwest Pathway interactions Pediatric Research Phenotype Phosphorylation Post-Translational Protein Processing Proteins Proteome Proteomics Relapse Resistance Resources Sampling Signal Pathway Standardization Toxic effect United States National Institutes of Health anticancer research cancer type driver mutation genome analysis high risk insight instrumentation leukemia malignant breast neoplasm multiple omics novel novel therapeutics open source precision oncology programs proteogenomics tandem mass spectrometry targeted treatment tumor

项目摘要

PROJECT SUMMARY The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Launched in 2011, CPTAC pioneered the integrated proteogenomic analysis of colorectal, breast and ovarian cancer to reveal new insights into these cancer types, such as identification of proteomic-centric subtypes, prioritization of driver mutations by correlative analysis of copy number alterations and protein abundance, and understanding cancer-relevant pathways through post- translational modifications. In this project, CPTAC will collaborate with the NIH Common Fund Gabriella Miller Kids First Pediatric Research Program (Kids First) to comprehensively characterize pediatric leukemia samples (such as T-cell acute lymphoblastic leukemia, T-ALL, and acute myeloid leukemia, AML) using mass spectrometry-based proteomics. This project will fully integrate proteogenomic information of such leukemia samples to capture and replicate specific cancer phenotype, better understand the interconnection of cancer pathways, identify novel protein targets for targeted therapies and immunotherapies, and to stimulate future pediatric cancer research and precision oncology. The PNNL PCC will perform comprehensive, integrated global proteome and phosphoproteome analyses of a total of 272 pediatric leukemia samples provided by the Kids First collaborators in various forms (such as cell pellets and surfaceome samples), using state-of-the-art liquid chromatography-tandem mass spectrometry instrumentation, highly multiplexed isobaric mass-tag labeling (TMT 18-plex), and integrated sample workflows. The resulting molecular data will become a community resource available at CAVATICA.

项目概要美国国家癌症研究所的临床蛋白质组学肿瘤分析联盟 (CPTAC) 是一项全国性的努力，旨在通过大规模蛋白质组的应用加速对癌症分子基础的理解 CPTAC 于 2011 年推出，率先推出了综合蛋白质组学。对结直肠癌、乳腺癌和卵巢癌的分析，揭示对这些癌症类型的新见解，例如识别以蛋白质组为中心的亚型，通过拷贝相关分析确定驱动突变的优先顺序数量变化和蛋白质丰度，并通过后期了解癌症相关途径翻译修饰。在该项目中，CPTAC 将与 NIH 共同基金 Gabriella Miller Kids First Pediatric 合作研究计划（儿童优先）全面表征儿童白血病样本（例如 T 细胞）急性淋巴细胞白血病 (T-ALL) 和急性髓系白血病 (AML) 使用基于质谱的方法该项目将充分整合此类白血病样本的蛋白质组学信息，以捕获和复制特定的癌症表型，更好地了解癌症途径的相互联系，识别新的靶向治疗和免疫疗法的蛋白质靶标，并刺激未来的儿科癌症研究和精准肿瘤学。 PNNL PCC 将对一个 Kids First 合作者以各种形式（例如细胞颗粒和表面组样品），使用最先进的液相色谱-串联质谱法仪器、高度多重同量异位质量标签标记 (TMT 18-plex) 和集成样品生成的分子数据将成为 CAVATICA 的社区资源。